The Oncology Weekly Publication Journal Oncotarget, LLC

Oncotarget, which was founded in 2010, is an open-access medical research journal weekly publication that covers all features of oncology. Mikhail Blagosklonny and Andrei V. Gudkov from the Roswell Cancer Institute are the editors in chief of Oncotarget. It is published by Impact Journals and is now a member of the Welcome Trust List of Compliant Publishers after meeting the Welcome Trust Publishers requirements. The journal gives a chance to medics who may have additional information to contribute. The journal was mainly set up to educate the general public about diseases especially cancer, through perceptive reviews that are shared on weekly publication. The definitive goal is to ensure these reviews go viral and reach as many people as possible and help them lead a life free of diseases. Oncotarget has mainly paid attention to all types of cancers publishing even the rare and types of cancer therapies and treatments to help people affected directly and indirectly by cancer.

The journal has also focused on the patient’s perspective of cancer urging them to stay positive, lead a satisfying and good quality of life in order to fight cancer as well as preventive measures. Intragen is a company that concentrates on the transformation of statistics from biological trials into genomic data and analogical tools for oncology. It announced a publication in oncotarget that shows the relationship between miR-31-3p expression levels with progressions free survival in metastatic colorectal cancer. This is the third most common cancer in males and second most common cancer in females patients. It is estimated that 25 percent of all colorectal cancer patients will show a metastatic disease at the time of diagnostic while 50 percent of the patient will exhibit developing mCRC during the initial findings. The publication stated that analyzing miR-31-3p expression levels in patients with RAS wild-type colorectal cancer can be used to test for patients who will benefit from targeted anti-EGFR therapy.

Intragen has lately announced the CE-IVD Marking and European commercial unveiling of the company’s miRpredX 31-3p kit which will be used to show the quantity of the MmiR-31-3p in Formalin-Fixed, Paraffin-Embedded (FFPE) tumor samples. The company also announced the CERBA Laboratories had signed a licensing agreement for the development of laboratory test measuring the expression of the miR-31-3p. The company’s primary goal is to decrypt the human genome to provide private laboratories and academic institutions with relevant data that can be easily interpreted for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy from the genetic makeup of a patient.Oncotarget is a journal that is positively impacting the world of healthcare through improving on research and coming up with better ways to cure diseases with an ultimate goal of a world free of diseases. It is an online platform where people who are working on the same potential cancer field from different worlds are brought together to collaboratively work together ensuring best results and research as well as uniting audiences from diverse backgrounds through their shared cancer research passion.